From the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 26;7(3). doi: 10.1212/NXI.0000000000000704. Print 2020 May.
To determine whether there are nuclear depletion and cellular mislocalization of RNA-binding proteins (RBPs) transactivation response DNA-binding protein of 43 kDa (TDP-43), fused in sarcoma (FUS), and polypyrimidine tract-binding protein (PTB) in MS, as is the case in amyotrophic lateral sclerosis (ALS) and oligodendrocytes infected with Theiler murine encephalomyelitis virus (TMEV), we examined MS lesions and in vitro cultured primary human brain-derived oligodendrocytes.
Nuclear depletion and mislocalization of TDP-43, FUS, and PTB are thought to contribute to the pathogenesis of ALS and TMEV demyelination. The latter findings prompted us to investigate these RBPs in the demyelinated lesions of MS and in in vitro cultured human brain-derived oligodendrocytes under metabolic stress conditions.
We found (1) mislocalized TDP-43 in oligodendrocytes in active lesions in some patients with MS; (2) decreased PTB1 expression in oligodendrocytes in mixed active/inactive demyelinating lesions; (3) decreased nuclear expression of PTB2 in neurons in cortical demyelinating lesions; and (4) nuclear depletion of TDP-43 in oligodendrocytes under metabolic stress induced by low glucose/low nutrient conditions compared with optimal culture conditions.
TDP-43 has been found to have a key role in oligodendrocyte function and viability, whereas PTB is important in neuronal differentiation, suggesting that altered expression and mislocalization of these RBPs in MS lesions may contribute to the pathogenesis of demyelination and neurodegeneration. Our findings also identify nucleocytoplasmic transport as a target for treatment.
确定是否存在 RNA 结合蛋白(RBPs)的核耗竭和细胞定位错误,这些 RBPs 包括反式激活反应 DNA 结合蛋白 43kDa(TDP-43)、肉瘤融合蛋白(FUS)和多嘧啶 tract 结合蛋白(PTB),这种情况在肌萎缩侧索硬化症(ALS)和感染 Theiler 鼠脑炎病毒(TMEV)的少突胶质细胞中已经得到证实,我们检查了 MS 病变和体外培养的原代人脑源性少突胶质细胞。
TDP-43、FUS 和 PTB 的核耗竭和定位错误被认为是 ALS 和 TMEV 脱髓鞘发病机制的原因。后者的发现促使我们在 MS 的脱髓鞘病变中和体外培养的人类脑源性少突胶质细胞中在代谢应激条件下研究这些 RBPs。
我们发现:(1)在一些 MS 患者的活动病变中,TDP-43 在少突胶质细胞中出现定位错误;(2)在混合活动/非活动脱髓鞘病变中,PTB1 在少突胶质细胞中的表达减少;(3)在皮质脱髓鞘病变中的神经元中,PTB2 的核表达减少;(4)与最佳培养条件相比,在低糖/低营养条件下诱导的代谢应激下,TDP-43 在少突胶质细胞中的核耗竭。
TDP-43 已被发现在少突胶质细胞功能和存活中起关键作用,而 PTB 在神经元分化中很重要,这表明这些 RBPs 在 MS 病变中的表达和定位错误可能导致脱髓鞘和神经退行性变的发病机制。我们的发现还确定了核质转运是治疗的靶点。